Previous 10 | Next 10 |
Osmotica Receives FDA Approval for Droopy Eyelid Treatment Osmotica Pharmaceuticals Plc ( OSMT ) reported that the FDA has given its approval for the company’s novel treatment for acquired blepharoptosis, or ptosis. Upneeq is now the only FDA-approved medical treatment for acquire...
IDEAYA Biosciences ( IDYA -2.4% ) has dosed the first patient in a Phase 1 clinical trial evaluating the combination of IDE196, a protein kinase C inhibitor and Pfizer's Mektovi (binimetinib), a MEK inhibitor, in metastatic uveal melanoma. More news on: IDEAYA Biosciences, ...
SOUTH SAN FRANCISCO, Calif. , July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of ...
SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics based on Synthetic Lethality, announced the appointment of Garret Hamp...
Last week was another good one for healthcare stocks across the board, and a stellar week for investors holding shares of these recent high flyers. Now that they've made some big gains, investors are right to wonder if there's more fuel in the tank. Here's what you need to know about what...
Gainers: Alpine Immune Sciences (NASDAQ: ALPN ) +174% . More news on: Alpine Immune Sciences, Inc., Aethlon Medical, Inc., Urban One, Inc., Stocks on the move, , Read more ...
Francesca's Holdings (NASDAQ: FRAN ) -24% on Q1 results . More news on: Francesca's Holdings Corporation, Medley Management Inc., Brickell Biotech, Inc., Stocks on the move, , Read more ...
IDEAYA Biosciences (NASDAQ: IDYA ) has priced its public offering of ~6.7M common shares at $15.00/share, for expected gross proceeds of $100M. More news on: IDEAYA Biosciences, Inc., Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , June 17, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share, before underwriting discou...
Repare Therapeutics ( RPTX ) has filed a preliminary prospectus for its IPO of 10M common shares at $18 - 20 per share. More news on: Repare Therapeutics, IDEAYA Biosciences, Inc., GlaxoSmithKline plc, Healthcare stocks news, IPO News, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...